PEGylated Chitosan Nanoparticles Loaded with Betaine and Nedaplatin Hamper Breast Cancer: In Vitro and In Vivo Studies.
Journal
ACS omega
ISSN: 2470-1343
Titre abrégé: ACS Omega
Pays: United States
ID NLM: 101691658
Informations de publication
Date de publication:
07 Nov 2023
07 Nov 2023
Historique:
received:
24
07
2023
accepted:
06
10
2023
medline:
16
11
2023
pubmed:
16
11
2023
entrez:
16
11
2023
Statut:
epublish
Résumé
The current study investigates the anticancer effects of PEGylated chitosan nanoparticles (CS NPs) coloaded with betaine (BT) and nedaplatin (ND) on breast adenocarcinoma (MCF-7) cells and breast cancer-bearing rats. Hereof, the ionotropic gelation approach was implemented for the synthesis of PEG-uncoated and PEG-coated CS NPs encompassing either BT, ND, or both (BT-ND). The sizes of the developed BT/CS NPs, ND/CS NPs, and BT-ND/CS NPs were 176.84 ± 7.45, 204.1 ± 13.6, and 201.1 ± 23.35 nm, respectively. Meanwhile, the sizes of the synthesized BT/PEG-CS NPs, ND/PEG-CS NPs, and BT-ND/PEG-CS NPs were 165.1 ± 32.40, 148.2 ± 20.98, and 143.7 ± 7.72 nm, respectively. The surface charges of the fabricated nanoparticles were considerably high. All of the synthesized nanoparticles displayed a spherical form and significant entrapment efficiency. Release experiments demonstrated that the PEGylated and non-PEGylated CS NPs could discharge their contents into the tumor cells' microenvironments (pH 5.5). In addition, the NPs demonstrated an outstanding ability to reduce the viability of the MCF-7 cell line. In addition, BT-ND/PEG-CS NPs were found to be the strongest among all NP preparations, where they caused around 90% decrease in the size of mammary gland tumors in rats compared to vehicle-treated animals.
Identifiants
pubmed: 37969975
doi: 10.1021/acsomega.3c05359
pmc: PMC10633871
doi:
Types de publication
Journal Article
Langues
eng
Pagination
41485-41494Informations de copyright
© 2023 The Authors. Published by American Chemical Society.
Déclaration de conflit d'intérêts
The authors declare no competing financial interest.
Références
Spectrochim Acta A Mol Biomol Spectrosc. 2018 Mar 15;193:528-536
pubmed: 29306207
Am J Clin Nutr. 2004 Sep;80(3):539-49
pubmed: 15321791
Int J Biol Macromol. 2022 Jun 15;210:565-578
pubmed: 35513093
Br J Cancer. 2014 Feb 4;110(3):808-16
pubmed: 24169354
ACS Nano. 2017 Sep 26;11(9):8560-8578
pubmed: 28829568
Polymers (Basel). 2019 Feb 12;11(2):
pubmed: 30960288
Arch Toxicol. 2005 Aug;79(8):451-60
pubmed: 15856183
Nanomaterials (Basel). 2021 Sep 18;11(9):
pubmed: 34578755
Pharmaceutics. 2023 Sep 22;15(10):
pubmed: 37896127
Pharmaceuticals (Basel). 2022 Feb 21;15(2):
pubmed: 35215372
J Mater Sci Mater Med. 2008 Dec;19(12):3525-33
pubmed: 18622769
Pharm Res. 1997 Oct;14(10):1431-6
pubmed: 9358557
Pharmaceutics. 2022 Jan 07;14(1):
pubmed: 35057040
Int J Biomater. 2018 Dec 30;2018:2952085
pubmed: 30693034
Cancer Manag Res. 2013 May 08;5:67-76
pubmed: 23696716
Int J Biol Macromol. 2018 Mar;108:753-764
pubmed: 29104049
J Phys Chem A. 2018 Aug 30;122(34):6934-6952
pubmed: 30071735
Mar Drugs. 2017 Dec 01;15(12):
pubmed: 29194378
Nanomaterials (Basel). 2021 Apr 09;11(4):
pubmed: 33918743
Pharmaceutics. 2022 Feb 13;14(2):
pubmed: 35214139
Acta Biomater. 2014 Feb;10(2):613-22
pubmed: 24211731
Jpn J Cancer Res. 2001 Jan;92(1):51-8
pubmed: 11173544
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Control Release. 2004 Oct 19;99(3):415-21
pubmed: 15451599
ACS Omega. 2022 Nov 07;7(46):42115-42125
pubmed: 36440163
J Cancer Res Clin Oncol. 2013 Mar;139(3):437-45
pubmed: 23143645
Cancer Cell. 2014 May 12;25(5):666-81
pubmed: 24768205
Pharmaceutics. 2021 Aug 27;13(9):
pubmed: 34575424
Science. 2005 Sep 2;309(5740):1559-63
pubmed: 16141072
Adv Drug Deliv Rev. 2018 May;130:17-38
pubmed: 30009886
Nanoscale. 2021 Jun 28;13(24):10748-10764
pubmed: 34132312
Nanoscale Adv. 2023 Sep 15;5(19):5399-5413
pubmed: 37767043
Pharmaceutics. 2020 Sep 10;12(9):
pubmed: 32927897
Int J Biol Macromol. 2019 Jun 1;130:997-1008
pubmed: 30844461
Basic Clin Pharmacol Toxicol. 2012 Aug;111(2):137-41
pubmed: 22429688
Pharmacol Res. 2010 Aug;62(2):90-9
pubmed: 20380880
Int J Nanomedicine. 2011;6:485-94
pubmed: 21562608
Nanomaterials (Basel). 2018 Jul 01;8(7):
pubmed: 29966380
Eur J Pharm Biopharm. 2008 May;69(1):388-95
pubmed: 18164928
CA Cancer J Clin. 2018 Nov;68(6):488-505
pubmed: 30328620
Biomater Sci. 2021 May 4;9(9):3209-3227
pubmed: 33949372
Molecules. 2020 Dec 14;25(24):
pubmed: 33327642
Int J Mol Sci. 2023 May 07;24(9):
pubmed: 37176099
Biomaterials. 2013 Dec;34(38):9952-9
pubmed: 24074837
ACS Omega. 2020 Nov 25;5(48):31456-31466
pubmed: 33324858
Pharmaceutics. 2022 Feb 15;14(2):
pubmed: 35214150
Eur J Pharm Biopharm. 2011 Nov;79(3):526-36
pubmed: 21736940
Eur J Pharm Sci. 2011 Sep 18;44(1-2):57-67
pubmed: 21704704
Inorg Chem. 2017 May 15;56(10):6013-6026
pubmed: 28452475
RSC Adv. 2021 Jul 14;11(40):24673-24680
pubmed: 35481025
JAMA. 2015 Oct 20;314(15):1599-614
pubmed: 26501536